UNSPSC 51273012: Alfentanil hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C21H32N6O3.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 11S92G0TIW, chemically known as propanamide, n-(1-(2-(4-ethyl-4,5-dihydro-5-oxo-1h-tetrazol-1-yl)ethyl)-4-(methoxymethyl)-4-piperidinyl)-n-phenyl-, monohydrochloride but more generally known as alfentanil hydrochloride, which bears US NIH Compound Identifier 64761. Alfentanil also comes in base form.

UNSPSC 51273012 Alfentanil hydrochloride is a Commodity code that in recent state and local procurement activity covers opioid-related pharmaceutical products and broader generic pharmaceutical supply arrangements rather than alfentanil specifically. State and local governments soliciting under this code are purchasing naloxone (an opioid antagonist), generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding, cooperative purchasing agreements, and exploratory requests for information aimed at direct-to-manufacturer prescription models. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement (administering the Minnesota Multistate Cooperative Purchasing Alliance) appear as recent active buyers. The work reflects a shift toward supply chain optimization and cost management in pharmaceutical procurement, with vendors expected to meet cGMP certification, Drug Supply Chain Security Act compliance, and specific insurance and logistics requirements including quarterly or ongoing delivery to designated facilities.

Recent solicitation activity spans Florida, Minnesota, Oregon (through MMCAP), and Texas. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic pharmaceuticals and OTC products through authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract awards effective July 1, 2026; evaluation criteria weighted price competitiveness at 75 percent and required vendors to maintain $5 million commercial general liability coverage. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for negotiated net pricing models outside traditional pharmacy benefit manager arrangements, representing an exploratory phase before formal procurement.